373 related articles for article (PubMed ID: 28666484)
1. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
J Biomol Struct Dyn; 2018 May; 36(6):1463-1478. PubMed ID: 28482755
[TBL] [Abstract][Full Text] [Related]
3. A study on quantitative structure-activity relationship and molecular docking of metalloproteinase inhibitors based on L-tyrosine scaffold.
Abbasi M; Ramezani F; Elyasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2015 Apr; 23(1):29. PubMed ID: 25925871
[TBL] [Abstract][Full Text] [Related]
4. Identification of New Hsp90 Inhibitors: Structure Based Virtual Screening, Molecular Dynamic Simulation, Synthesis and Biological Evaluation.
Abbasi M; Amanlou M; Aghaei M; Hassanzadeh F; Sadeghi-Aliabadi H
Anticancer Agents Med Chem; 2021; 21(18):2583-2591. PubMed ID: 33563187
[TBL] [Abstract][Full Text] [Related]
5. Towards the In-silico Design of New HSP90 Inhibitors: Molecular Docking and 3D-QSAR CoMFA Studies of Tetrahydropyrido [4, 3-d] Pyrimidine Derivatives as HSP90 Inhibitors.
Sepehri B; Ghavami R
Med Chem; 2018; 14(5):439-450. PubMed ID: 29564982
[TBL] [Abstract][Full Text] [Related]
6. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors.
Zhang C; Wang X; Liu H; Zhang M; Geng M; Sun L; Shen A; Zhang A
Eur J Med Chem; 2017 Jan; 125():315-326. PubMed ID: 27688186
[TBL] [Abstract][Full Text] [Related]
8. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
9. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent.
Mollazadeh S; Shamsara J; Iman M; Hadizadeh F
Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 5,6-dihydro-4H-benzo[d]isoxazol-7-one and 5,6-dihydro-4H-isoxazolo[5,4-c]pyridin-7-one derivatives as potential Hsp90 inhibitors.
Musso L; Cincinelli R; Giannini G; Manetti F; Dallavalle S
Chem Biol Drug Des; 2015 Nov; 86(5):1030-5. PubMed ID: 25855505
[TBL] [Abstract][Full Text] [Related]
11. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods.
Liu J; Wang F; Ma Z; Wang X; Wang Y
Int J Mol Sci; 2011 Jan; 12(2):946-70. PubMed ID: 21541036
[TBL] [Abstract][Full Text] [Related]
12. The in silico identification of potent anti-cancer agents by targeting the ATP binding site of the N-domain of HSP90.
Sepehri B; Rezaei M; Ghavami R
SAR QSAR Environ Res; 2018 Jul; 29(7):551-565. PubMed ID: 30058412
[TBL] [Abstract][Full Text] [Related]
13. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study.
Roy KK; Singh S; Saxena AK
Mol Divers; 2011 May; 15(2):477-89. PubMed ID: 20740314
[TBL] [Abstract][Full Text] [Related]
14. Docking and QSAR analysis of tetracyclic oxindole derivatives as α-glucosidase inhibitors.
Asadollahi-Baboli M; Dehnavi S
Comput Biol Chem; 2018 Oct; 76():283-292. PubMed ID: 30103106
[TBL] [Abstract][Full Text] [Related]
15. Identification of the naphthoquinone derivative inhibitors binding site in heat shock protein 90: an induced-fit docking, molecular dynamics and 3D-QSAR study.
Godoy-Castillo C; Bravo-Acuña N; Arriagada G; Faunes F; León R; Soto-Delgado J
J Biomol Struct Dyn; 2021 Oct; 39(16):5977-5987. PubMed ID: 32799638
[TBL] [Abstract][Full Text] [Related]
16. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
17. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90.
Gopalsamy A; Shi M; Golas J; Vogan E; Jacob J; Johnson M; Lee F; Nilakantan R; Petersen R; Svenson K; Chopra R; Tam MS; Wen Y; Ellingboe J; Arndt K; Boschelli F
J Med Chem; 2008 Feb; 51(3):373-5. PubMed ID: 18197612
[TBL] [Abstract][Full Text] [Related]
18. 2D- and 3D-QSAR modelling, molecular docking and
Shukla A; Tyagi R; Meena S; Datta D; Srivastava SK; Khan F
J Biomol Struct Dyn; 2020 Jan; 38(1):168-185. PubMed ID: 30686140
[TBL] [Abstract][Full Text] [Related]
19. Identification of potent aldose reductase inhibitors as antidiabetic (Anti-hyperglycemic) agents using QSAR based virtual Screening, molecular Docking, MD simulation and MMGBSA approaches.
Bakal RL; Jawarkar RD; Manwar JV; Jaiswal MS; Ghosh A; Gandhi A; Zaki MEA; Al-Hussain S; Samad A; Masand VH; Mukerjee N; Nasir Abbas Bukhari S; Sharma P; Lewaa I
Saudi Pharm J; 2022 Jun; 30(6):693-710. PubMed ID: 35812153
[TBL] [Abstract][Full Text] [Related]
20. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
